Clinical Trials
26 trialsNCT07025512 2026-05-08
177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT06284460 2026-02-13
Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT06098755 2026-02-04
The Sequestration of Holistic Stress Management Techniques for Adults
Virtual Tribunal Monastery
Phase NA Withdrawn
NCT06254742 2025-08-07
A Trial of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of Chemotherapy-related Moderate to Severe Neutropenia of Patients With Nonmyeloid Malignancies
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Withdrawn
NCT06508827 2025-07-09
Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma
Indiana University
Phase 2 Withdrawn
NCT01660347 2025-05-02
Donor Stem Cell Boost in Treating Patients With Low Blood Cells After Donor Stem Cell Transplant
Thomas Jefferson University
Phase NA Withdrawn
NCT04260230 2024-12-30
REACT
The Christie NHS Foundation Trust
Phase NA Withdrawn
NCT05784844 2024-09-19
Antimicrobial Revision in Persistent Febrile Neutropenia
Wake Forest University Health Sciences
Phase 4 Withdrawn
NCT05829434 2024-02-12
MAGROLIC
University of Leipzig
Phase 2 Withdrawn
NCT05927012 2023-11-24
A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia).
Keros Therapeutics, Inc.
Phase 2 Withdrawn
NCT05261646 2023-09-28
A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tumours, Who Are Delayed for at Least 1 Week From Their Scheduled Cycle Because of Chemotherapy-induced Thrombocytopenia
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Withdrawn
NCT00816413 2023-08-14
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer
University of Nebraska
Phase 1/2 Withdrawn
NCT05061654 2023-08-14
CEF-10
Hamad Medical Corporation
Phase 4 Withdrawn
NCT04331483 2022-02-28
EVAADE
Centre Leon Berard
Phase NA Withdrawn
NCT03988231 2021-10-08
Enoxaparin Versus Placebo for Venous Thromboembolism Prevention in Low Risk Cancer Patients After Surgical Procedures: a Randomized, Double Blind, Placebo Controlled Clinical Trial Pilot Study
University of Utah
Phase 4 Withdrawn
NCT00127543 2021-01-05
Kid Cards: Teaching Kids About Medicines
Children's Mercy Hospital Kansas City
Phase NA Withdrawn
NCT04437953 2020-12-08
Avatrombopag for Thrombocytopenia in People With Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Withdrawn
NCT03086252 2018-07-26
Patient-Driven Transfusion Thresholds in Hematological Disorders: A Pilot Study
Emory University
Phase NA Withdrawn
NCT00481624 2018-03-05
Procrit
University of Louisville
Phase 2 Withdrawn
NCT02765997 2017-12-05
StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies
Masonic Cancer Center, University of Minnesota
Phase 2 Withdrawn
NCT01163201 2017-12-02
T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies
Masonic Cancer Center, University of Minnesota
Phase 1/2 Withdrawn
NCT02805868 2016-10-24
Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis
Northwestern University
Phase EARLY_PHASE1 Withdrawn
NCT00081055 2014-12-04
OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies
Mesoblast, Ltd.
Phase 2 Withdrawn
NCT01450241 2013-06-07
Short-term Antibiotic Treatment for Unexplained Fever in Solid Cancer Patients With Febrile Neutropenia
Rabin Medical Center
Phase NA Withdrawn
NCT00301912 2012-10-02
Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
University of California, San Francisco
Phase 2 Withdrawn
NCT01206907 2012-08-17
Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric Subjects
Endo Pharmaceuticals
Phase 3 Withdrawn